Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Authors
  • Di Leo, Angelo
  • Jerusalem, Guy
  • Petruzelka, Lubos
  • Torres, Roberto
  • Bondarenko, Igor N
  • Khasanov, Rustem
  • Verhoeven, Didier
  • Pedrini, José L
  • Smirnova, Iya
  • Lichinitser, Mikhail R
  • Pendergrass, Kelly
  • Garnett, Sally
  • Lindemann, Justin P O
  • Sapunar, Francisco
  • Martin, Miguel
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Oct 20, 2010
Volume
28
Issue
30
Pages
4594–4600
Identifiers
DOI: 10.1200/JCO.2010.28.8415
PMID: 20855825
Source
Medline
License
Unknown

Abstract

Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.

Report this publication

Statistics

Seen <100 times